Fig. 6 | Signal Transduction and Targeted Therapy

Fig. 6

From: Preclinical and first-in-human of purinostat mesylate, a novel selective HDAC I/IIb inhibitor, in relapsed/refractory multiple myeloma and lymphoma

Fig. 6

PM in phase I clinical trials for treating r/r MM and r/r lymphoma patients. a Schematic diagram of PM therapy administration for r/r MM and lymphoma patients. b Average plasma concentration-time semi-logarithmic curves of PM in clinical phase I patients. After a single intravenous infusion (top) or at specified times before and after the last dose of the multiple-dose phase (Day 15, bottom), UPLC-MS/MS was employed to detect the concentration of PM in plasma. All data are represented as mean ± SD. c Phase I clinical trial efficacy responses of PM in patients with r/r MM, r/r lymphoma, and r/r DLBCL. d PET-CT images of a patient with r/r DEL DLBCL (No.26, 15 mg/m2) and r/r FL (No.18, 11.2 mg/m2) at the screening and different stages after PM treatment. e Serum cytokine levels in r/r MM (n = 2) and r/r lymphoma (n = 2) patients before and after one week of PM administration. f Proportion of T cells in PB leukocytes in r/r MM (n = 2) and r/r lymphoma (n = 2) patients before and after 1 week of PM administration. Data are represented as mean ± SEM. *p < 0.05, ***p < 0.001, t test

Back to article page